The clinical trial is designed to assess the intrapulmonary penetration and pharmacokinetics of Zolyd to support future development as a treatment for US patients with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia infections.
NIAID, part of the National Institutes of Health, plans to initiate a Phase 1 trial in the fourth quarter of 2017 to determine the intrapulmonary pharmacokinetics of Zolyd after multiple doses in 36 healthy subjects. This trial will be conducted by the Vaccine and Treatment Evaluation Unit (VTEU) at Duke University.
The network of VTEUs is supported by NIAID. Zavante will supply the investigational product that will be tested in this trial.
The trial will measure Zolyd's pulmonary penetration by assessing drug concentrations in the lining of subjects' bronchial pathways. Prior preclinical and clinical investigations of intravenous fosfomycin demonstrate that it penetrates rapidly into tissues and achieves clinically relevant concentrations in serum, urine, soft tissues, lungs and other organs, potentially making it a versatile antibiotic treatment option.
The NIAID-supported trial will also seek to provide additional data regarding the safety and tolerability of a contemporary dosing regimen (6 grams every 8 hours), which may support further evaluations of Zolyd in the intended patient populations.
Zolyd, an investigational, first-in-class injectable epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most multi-drug resistant strains that are of particular concern to public health, has a differentiated mechanism of action that acts at an earlier step in cell wall synthesis inhibition, providing activity against pathogens that are often resistant to other classes of antibiotics.
Zavante recently reported that Zolyd met the primary endpoint of statistical non-inferiority to piperacillin/tazobactam in the pivotal ZEUS Phase 2/3 clinical trial in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. The company plans to submit a New Drug Application to the FDA in early 2018.
Zavante Therapeutic is a privately-held, late clinical-stage biopharmaceutical company focused on developing novel therapies to improve the outcomes of hospitalized patients.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial